Abstract
Raltegravir was the first available integrase inhibitor for treating HIV-positive patients. This review aims to provide an overview of its role in the management of HIV-1 infection, highlighting its key pharmacokinetic and pharmacodynamic properties.
| Original language | English |
|---|---|
| Pages (from-to) | 1167-1176 |
| Number of pages | 10 |
| Journal | Expert Opinion on Drug Metabolism and Toxicology |
| Volume | 11 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- drug-to-drug interactions
- pharmacodynamic
- pharmacokinetic
- raltegravir
- resistance
Fingerprint
Dive into the research topics of 'Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver